News and Perspective

• Treating Breast Cancer During COVID-19: 'Indispensable' In the midst of a pandemic, how can oncologists best continue therapy for their patients with breast cancer? The experts define treatment protocols and priorities.
  Medscape Oncology, August 06, 2020
• Time to Stop Pressuring Women on Screening Mammography?   New research suggests that screening mammography might not be the key to lower breast cancer mortality.
  Medscape Ob/Gyn, July 30, 2020
• New MBC Treatments: Triple-Negative; HER2+; and ER+, HER2- The latest therapeutic options improve progression-free survival for some patients.
  Medscape Oncology, July 16, 2020
• Key Studies in Metastatic Breast Cancer From ASCO 2020   Key studies in metastatic breast cancer from ASCO 2020 focus on first-line checkpoint inhibition in TNBC; also, updated evidence that tucatinib plus chemotherapy benefits women with HER2+ disease.
  Medscape, June 23, 2020
• ASCO 2020'Unbelievably Exciting' Results in Rare Type of Breast Cancer Three (of 17) women with advanced metaplastic breast cancer treated with a combination of immunotherapies showed dramatic and durable responses.
  Medscape Medical News, June 19, 2020
• Metastatic Breast Cancer Symptom Management: 5 Things to Know By addressing MBC patients' perspectives on meaningful symptom improvement and priorities for symptom management, oncologists can ensure treatment is consistent with patient values and goals.
  Medscape Oncology, June 18, 2020
• ASCO 2020Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.
  Medscape Medical News, May 31, 2020
• ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
  Medscape Oncology, May 29, 2020
• Positive Strides in Triple-Negative Breast Cancer: Increased Options for Advanced Disease   Experts report on developments that could extend progression-free survival and improve quality of life for women with metastatic triple-negative breast cancer.
  Medscape TV, May 27, 2020
• Virtual ASCO Levels the Playing Field for Oncologists Everywhere Like everything in oncology, a virtual ASCO meeting is a tradeoff between benefits and disadvantages. But it may be a big win for oncologists in resource-strapped settings, argues Dr Bishal Gyawali.
  Medscape Oncology, May 22, 2020
• Onc Daily: Oncologists' Income Up, Prostate Cancer on the Rise These are the most important oncology stories you need to know about today.
  Medscape Medical News, May 21, 2020
• Alert First PARP Inhibitor Approved for Metastatic Prostate Cancer The FDA has granted rucaparib (Rubraca) an accelerated approval for use in BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer.
  FDA Approvals, May 19, 2020
• Mammography Cuts Risk for Fatal Breast Cancers: New Data Regular screening reduced the risk for both fatal and advanced breast cancer, shows a study from Sweden involving half a million women.
  Medscape Medical News, May 12, 2020
• Onc Daily: DPD Testing Advised, Free Parking at Cancer Centers These are the most important oncology stories you need to know about today.
  Medscape Medical News, May 05, 2020
• Leptomeningeal Carcinomatosis in Breast Cancer Leptomeningeal carcinomatosis has been understudied for years, and its increasing prevalence now has researchers working overtime to make much-needed progress in its treatment.
  Medscape Oncology, May 05, 2020
• AACR 2020Novel Immune Activator Boosts Immunotherapy Benefit in TNBC The combination of a novel immune activator with pembrolizumab showed good activity, especially in women with disease that converted to triple negative after endocrine therapy.
  Medscape Medical News, April 30, 2020
• Cancer Diagnosis and Treatment Upended by COVID-19, Says CRUK The pandemic has severely affected cancer screening, diagnosis, and treatment, resulting in patients being undiagnosed and untreated, warns Cancer Research UK.
  Medscape Medical News, April 28, 2020
• Positive Strides in Triple-Negative Breast Cancer: Neoadjuvant Advances   Experts discuss standard therapy for early TNBC, the newly approved neoadjuvant immunotherapy regimen, and the option to de-escalate therapy in select patients.
  Medscape TV, April 24, 2020
• Alert FDA OKs New Drug for Triple-Negative Breast Cancer A novel antibody-drug conjugate is now available for metastatic triple-negative breast cancer.
  FDA Approvals, April 22, 2020
• Alert FDA Approves First New Breast Cancer Drug With International Group The approval is for the oral therapy tucatinib (Tukysa, Seattle Genetics) for the treatment of advanced HER2-positive breast cancer.
  FDA Approvals, April 17, 2020